Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release mat
Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
대표청구항▼
1. A solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse, wherein the cores are(i) dispersed in a matrix comprising a controlled release material or(ii) coated with a controlled release material,wherein the dosag
1. A solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse, wherein the cores are(i) dispersed in a matrix comprising a controlled release material or(ii) coated with a controlled release material,wherein the dosage form further comprises from about 0.05% to about 15% (w/w) of an internal adhesion promoter to promote the adhesion of the active agent and the controlled release material, andwherein the amount of active agent released from the dosage form after crushing is within 30% of the amount of active agent released from the dosage form before crushing when measured at 4 hours using a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37° C. 2. The solid oral dosage form of claim 1, wherein the core further comprises a dissolution enhancer. 3. The solid oral dosage form of claim 1, wherein the coating or matrix further comprises a pore former. 4. The solid oral dosage form of claim 1, further comprising an alcohol resistant material. 5. The solid oral dosage form of claim 1, further comprising an external adhesion promoter. 6. The solid oral dosage form of claim 1, wherein the controlled release material is a polymer. 7. The solid oral dosage form of claim 5, wherein the internal adhesion promoter and external adhesion promoter are selected from the group consisting of a cellulosic material, a surfactant, a carbomer and a mixture thereof. 8. The solid oral dosage form of claim 2, wherein the dissolution enhancer is selected from the group consisting of a cellulosic material, a sugar, a starch and a polymer. 9. The solid oral dosage form of claim 3, wherein the pore former is selected from the group consisting of sodium chloride, a polysaccharide, a polymer, an organic solvent and an inorganic material. 10. The solid oral dosage form of claim 1, wherein the plurality of particles are compressed into a tablet having a breaking strength of less than 400N. 11. The solid oral dosage form of claim 1, wherein the weight ratio of the active agent to the controlled release material is from about 2:1 to about 1:100. 12. The solid oral dosage form of claim 1, wherein the particles have a mean diameter from about 0.01 mm to about 3 mm. 13. The solid oral dosage form of claim 1, comprising from about 0.1% to about 80% (w/w) active agent. 14. The solid oral dosage form of claim 1, comprising from about 10% to about 90% (w/w) controlled release material. 15. The solid oral dosage form of claim 1, comprising from about 0.1% to about 5% (w/w) internal adhesion promoter. 16. The solid oral dosage form of claim 1, comprising from about 1% to about 40% (w/w) dissolution enhancer. 17. The solid oral dosage form of claim 1, comprising from about 0.5% to about 25% (w/w) pore former. 18. The solid oral dosage form of claim 1, comprising from about 1% to about 50% (w/w) alcohol resistant material. 19. The oral dosage form of claim 1, which provides a dissolution release rate in-vitro of the active agent, when measured by the USP Type 2, Paddle Method at 50 rpm in 900 ml Simulated Gastric Fluid (SGF) without enzymes at 37° C. of at least about 15% by weight of the active agent released at 1 hour, from about 25% to about 65% by weight of the active agent released at 2 hours, from about 45% to about 85% by weight of the active agent released at 4 hours, and at least about 60% by weight of the active agent released at 8 hours. 20. The oral dosage form of claim 1, wherein the amount of active agent released at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is within 30% of the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°. 21. The oral dosage form of claim 1, wherein the amount of active agent released at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is less than the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°. 22. The oral dosage form of claim 1, wherein the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 50%, 40%, 30% or 20% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°. 23. The solid oral dosage form of claim 1, wherein the recovery of the active agent is less than about 50% based on a syringability test whereby the dosage form is crushed and mixed with 5 or 10 mL solvent and the resultant solution is aspirated with a 18, 22, 25, or 27 gauge needle. 24. The solid oral dosage form of claim 1, wherein the active agent is selected from the group consisting of opioid agonists, tranquilizers, CNS depressants, CNS stimulants, sedative hypnotics, and mixtures thereof. 25. The solid oral dosage form of claim 1, further comprising an aversive agent. 26. The solid oral dosage form of claim 25, wherein the aversive agent is selected from the group consisting of emetics, antagonists, bittering agents, irritants, gelling agents and mixtures thereof. 27. A solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an opioid agonist and a carbomer, wherein the cores are (i) dispersed in a matrix comprising a neutral acrylic polymer and a pore former (ii) coated with a neutral acrylic polymer and a pore former; wherein the carbomer is present in the solid oral dosage form at a concentration ranging from about 0.05% to about 15% (w/w), and wherein the dosage form further comprises a dissolution enhancer. 28. A process for preparing a solid oral dosage form comprising preparing a plurality of particles by (i) granulating an opioid agonist and a carbomer to form core granules;(ii) coating or granulating the core granules with a neutral acrylic polymer and lactose to obtain controlled release particles or granules;(iii) coating or granulating the controlled release particles or granules with methylcellulose and a carbomer to obtain alcohol resistant controlled release particles or granules; and(iv) compressing the alcohol resistant controlled release particles or granules into a tablet,wherein the carbomer is present in the solid oral dosage form at a concentration ranging from about 0.05% to about 15% (w/w)wherein the amount of opioid agonist released from the solid dosage form after crushing is within 30% of the amount of opioid agonist released from the solid dosage form before crushing when measured at 4 hours using a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37° C. 29. A method of management of both acute and chronic conditions comprising administering a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse, wherein the cores are(i) dispersed in a matrix comprising a controlled release material or(ii) coated with a controlled release material,wherein the dosage form further comprises from about 0.05% to about 15% (w/w) of an internal adhesion promoter to promote the adhesion of the active agent and the controlled release material,wherein the internal adhesion promoter is selected from the group consisting of a cellulosic material, a surfactant, a carbomer and a mixture thereof, andwherein the amount of active agent released from the solid dosage form after crushing is within 30% of the amount of active agent released from the solid dosage form before crushing when measured at 4 hours using a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37° C. 30. The solid oral dosage form of claim 1, wherein the extraction at 60 minutes is less than about 90% based on both heated and unheated extraction tests, whereby the dosage form is mixed or crushed and mixed with 30 mL of a solvent selected from a group consisting of water, pH 3 buffer, pH 10 buffer, 40% ethanol, and cooking oil.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (227)
Khanna Ish K. (Vernon Hills IL) Weier Richard M. (Lake Bluff IL) Collins Paul W. (Deerfield IL) Yu Yi (Skokie IL) Xu Xiangdong (Evanston IL) Partis Richard A. (Evanston IL) Koszyk Francis J. (Prospec, 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation.
Black Cameron (Pointe Claire CAX) Mancini Joseph A. (St. Leonard CAX) Lau Cheuk K. (Ile Bizard CAX) Prasit Petpiboon (Kirkland CAX) Vickers Philip J. (Pierrefonds CAX 4), 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents.
Hirsh,Jane; Kibanov,Alexander M.; Swager,Timothy M.; Buchwald,Stephen L.; Lo,Whe Yong; Fleming,Alison B.; Rariy,Roman V., Abuse-deterrent pharmaceutical compositions of opiods and other drugs.
Black W. Cameron (Pointe-Claire CAX) Li Chun-Sing (Dollard Des Ormeaux CAX) Guay Daniel (Notre Dame de L\lle Perrot CAX) Prasit Petpiboon (Kirkland CAX) Roy Patrick (Dollard Des Ormeaux CAX), Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) McGinity James (Austin TX) Bodmeier Roland (Austin TX), Aqueous dispersions of zein and preparation thereof.
Gauthier Jacques Y. (Laval CAX) Lau Cheuk K. (Ile Bizard CAX) LeBlanc Yves (Kirkland CAX) Li Chun-Sing (Dollard des Ormeaux CAX) Roy Patrick (Dollard des Ormeaux CAX) Therien Michel (Laval CAX) Wang , Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents.
Leshchiner Edward (Cresskill NJ) Balazs Endre A. (Fort Lee NJ) Larsen Nancy E. (Highland Mills NY) Leshchiner Adelva (Cresskill NJ), Biocompatible viscoelastic gel slurries, their preparation and use.
Iwasaki Tameo (Nishinomiya JPX) Nishitani Takashi (Toyonaka JPX) Ohtani Akio (Kawaguchi JPX) Inamasu Masanori (Misato JPX), Butadiene derivatives and process for using the same.
Abramowitz Robert (Cranbury NJ) Ranadive Sunanda A. (East Brunswick NJ) Varia Sailesh A. (Plainsboro NJ) Jain Nemichand B. (Cranbury NJ), Colonic drug delivery system.
Kuczynski Anthony L. ; Childers Jerry D. ; Barclay Glen E. ; Rodriguez Susan ; Merrill Sonya, Composition and dosage form comprising opioid antagonist.
Blumberg Peter M. (Frederick MD), Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitizat.
Drust Eugene G. (Norwich NY) Kasting Gerald B. (Wyoming OH) Smith Ronald L. (West Chester OH) Szkutak Joan B. (West Chester OH), Compositions for the transdermal delivery of pharmaceutical actives.
Oshlack Benjamin (New York NY) McGinity James (Austin TX) Chasin Mark (Manalapan NJ) Bodmeier Roland (Austin TX), Controlled release coatings derived from aqueous dispersions of zein.
Goldie Robert S. (Cambridge GB2) Malkowska Sandra T. A. (Cambridge GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release dihydrocodeine composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Thinnayam N. Krishnamurthy CA; Andrew Darke CA, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
Goldie Robert S. (Comberton GB2) Malkowska Sandra T. A. (Landbeach GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Goldie Robert S. (Comberton GBX) Malkowska Sandra T. A. (Landbeach GBX) Leslie Stewart T. (Cambridge GBX) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John Joseph (Mount Vernon NY) Kaiko Robert Francis (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled-release formulations coated with aqueous dispersions of ethylcellulose.
Prasit Petpiboon (Kirkland CAX) Guay Daniel (Iie Perrot CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollar des Ormeaux CAX) Therien Michel (Laval CAX), Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2.
Bjork, Anders K. K.; Olsson, Knut G.; Abramo, Aina L.; Christensson, Erik G., Diphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods.
Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke, Drug delivery system for averting pharmacokinetic drug interaction and method thereof.
Han, Chien-Hsuan; Hou, Sui Yuen Eddie; Reid, Monica L., Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
Mayer, David J.; Price, Donald D.; Mao, Jianren; Lyle, John W., Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance.
Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Inhibiting the development of tolerance to and/or dependence on an addictive substance.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other o.
Sackler Richard S. (Greenwich CT) Kaiko Robert F. (Weston CT) Goldenheim Paul (Wilton CT), Method of treating pain by administering 24 hour oral opioid formulations.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Kumar, Vijai; Dixon, David; Tewari, Divya; Wadgaonkar, Dilip B., Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof.
Colombo Paolo (Milan ITX) Cardona Antonio C. (Milan ITX) Pifferi Giorgio (Milan ITX), Multilayer matrix systems for the controlled release of active principles.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Belley Michel (Pierrefonds CAX), N-benzyl-3-indoleacetic acids as antiinflammatory drugs.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques Y. (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducharme, N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors.
Houn Simon Hsia ; David Fan, Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates.
Shaw Irving F. (East Rockaway NY) Berk Jerome (New Rochelle NY), Orally administered drug composition for therapy in the treatment of narcotic drug addiction.
Wong Patrick S. L. (Hayward CA) Barclay Brian L. (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device for administering certain drugs.
Wong Patrick S. L. (Hayward CA) Barclay Brian (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device with dual thermodynamic activity.
Guillaumet Grald (Orleans FRX) Flouzat Christine (Clermont Ferrand FRX) Devissaguet Michelle (Neuilly sur Seine FRX) Renard Pierre (Versailles FRX) Caignard Daniel H. (Paris FRX) Adam Grard (le Mesni, Oxazolopyridine compounds, compositions and use.
Fukunaga Atsuo F. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274) Funuknaga Alex S. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274), Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine.
Batt Douglas G. (Wilmington DE) Pinto Donald J. P. (Newark DE) Orwat Michael J. (Wilmington DE) Petraitis Joseph J. (Glenmoore PA) Pitts William J. (Newark DE), Prostaglandin synthase inhibitors.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Jackson Heights NY) Gaylord Norman G. (New Providence NJ), Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose.
Staniforth John N.,GB2 ; Sherwood Bob E. ; Hunter Edward A., Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility.
Chien Yie W. (North Brunswick NJ) Chiang Chin-Chih (Piscataway NJ) Tojo Kabuji (Highland Park NJ), Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Hille Thomas (Neuwied DEX) Deurer Lothar (Koblenz DEX) Hoffmann Hans-Rainer (Neuwied DEX), Transdermal therapeutic system comprising as active component buprenorphine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.